Cullinan Therapeutics, Inc. (CGEM)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cullinan Therapeutics, Inc. (CGEM) trades at $14.06 with AI Score 46/100 (Weak). Cullinan Therapeutics, Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on oncology and immuno-oncology therapies, currently trading with a market cap of $642 million. Market cap: 851M.
Last analyzed: Jan 20, 2026Cullinan Therapeutics, Inc. Company Overview
Cullinan Therapeutics is a clinical-stage biopharmaceutical firm pioneering oncology and immuno-oncology therapies, aiming to disrupt the market with its innovative pipeline and strategic approach.
Investment Thesis
Cullinan Therapeutics, with its B- rating, presents a speculative investment opportunity based on the potential success of its clinical pipeline, particularly with an average analyst price target of $31 suggesting significant upside. The company's focus on novel oncology and immuno-oncology therapies could provide substantial growth catalysts if clinical trials are successful, offering a competitive moat in a high-demand market.
Based on FMP financials and quantitative analysis
Competitors & Peers
Strengths
- Strong current ratio of 10.45 indicates financial stability
- Focus on innovative oncology and immuno-oncology therapies
- Experienced leadership team with expertise in drug development
Weaknesses
- Negative ROE of -41.6% indicates poor profitability
- Reliance on successful clinical trial outcomes
- Limited commercialized products and revenue streams
Catalysts
- CLN-978 Phase 1/2 data release (Q3 2026)
- Potential FDA approval for Zipalertinib CLN-081/TAS6417 (Ongoing)
Risks
- Clinical trial failure risk
- Regulatory approval risk
- Competition from larger pharmaceutical companies
Growth Opportunities
- CLN-978 clinical trial results for B-cell malignancies (H2 2026)
- Expansion into new oncology indications with existing pipeline assets (Market size: $100B+)
- Strategic partnerships with larger pharmaceutical companies for commercialization
- Development of novel combination therapies to enhance efficacy of existing treatments
Opportunities
- Positive clinical trial results for key pipeline assets
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new oncology indications
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and approval delays
- Clinical trial failures and setbacks
Competitive Advantages
- Intellectual property protection for novel therapies
- Strong pipeline of differentiated oncology assets
About CGEM
Cullinan Therapeutics, Inc. (CGEM), founded in 2016 by Patrick A. Baeuerle, is a clinical-stage biopharmaceutical company headquartered in Cambridge, MA, with a team of 111 employees. With a market capitalization of $642 million, Cullinan is dedicated to developing innovative oncology and immuno-oncology therapies. Their pipeline includes assets like CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617, targeting various cancer indications. The company aims to address unmet medical needs by focusing on precision oncology and novel immunotherapies. Cullinan's competitive advantage lies in its experienced leadership team and its focus on developing differentiated therapies with the potential to improve patient outcomes.
What They Do
- Develop novel oncology therapies
- Conduct clinical trials
- Seek regulatory approvals
Business Model
- Out-licensing or partnering with larger pharmaceutical companies
- Direct sales of approved therapies
- Government grants and funding for research and development
Key Customers
- Oncology patients
- Hospitals and cancer centers
- Payers (insurance companies)
Financials
Chart & Info
Cullinan Therapeutics, Inc. (CGEM) stock price: $14.06 (+0.42, +3.08%)
Latest News
-
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data
defenseworld.net · Mar 14, 2026
-
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $36
benzinga · Mar 11, 2026
-
Cullinan Therapeutics: Q4 Earnings Insights
benzinga · Mar 10, 2026
-
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
MT Newswires · Mar 10, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CGEM.
Price Targets
Consensus target: $31.80
MoonshotScore
What does this score mean?
The MoonshotScore rates CGEM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $36
Cullinan Therapeutics: Q4 Earnings Insights
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
Common Questions About CGEM
What does CGEM do?
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology and immuno-oncology therapies. They conduct research, develop drug candidates, and perform clinical trials to bring new treatments to market for cancer patients.
Who are CGEM's main competitors?
CGEM's main competitors include ADC Therapeutics S.A. (ADCT) in the antibody-drug conjugate space and Bicycle Therapeutics plc (BCYC) in novel peptide therapeutics. These companies are developing competing therapies for similar indications.
What is CGEM's competitive advantage?
CGEM's competitive advantage lies in its focus on precision oncology and immuno-oncology, developing differentiated therapies with the potential to improve patient outcomes. Their strong pipeline and experienced leadership team also contribute to their competitive position.
How does CGEM make money?
CGEM primarily generates revenue through out-licensing or partnering with larger pharmaceutical companies to commercialize its therapies. They may also receive government grants and funding for research and development. Future revenue will depend on successful commercialization of their pipeline assets.
Is CGEM profitable?
No, CGEM is not currently profitable. Their ROE is -41.6%, indicating significant losses. As a clinical-stage company, they are investing heavily in research and development, which impacts their profitability in the short term.
What are the key factors to evaluate for CGEM?
Cullinan Therapeutics, Inc. (CGEM) currently holds an AI score of 46/100, indicating low score. Analysts target $31.80 (+126% from $14.06). Key strength: Strong current ratio of 10.45 indicates financial stability. Primary risk to monitor: Clinical trial failure risk. This is not financial advice.
How frequently does CGEM data refresh on this page?
CGEM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CGEM's recent stock price performance?
Recent price movement in Cullinan Therapeutics, Inc. (CGEM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $31.80 implies 126% upside from here. Notable catalyst: Strong current ratio of 10.45 indicates financial stability. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on specific clinical trial timelines and competitive landscape.